Top Markets
#1 MowCat MowCat +48.96%
#2 Audiera Audiera +28.09%
#3 Velvet Velvet +27.19%
#4 Bermuda Shorts Bermuda Shorts +24.66%
#5 Biconomy Biconomy +22.49%
#6 aPriori aPriori +22.35%
#7 Quack AI Quack AI +21.37%
#8 Derive Derive +19.47%
#9 SkyAI SkyAI +14.21%
#10 Geodnet Geodnet +12.98%
Coin of the day
MowCat MowCat
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Classificação em ações #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Preço da ação
$2.70
Última sincronização: 2023-05-17
Valor de mercado
$4.13M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Graybug Vision, Inc. (GRAY)

Categoria

Healthcare
Lucros da Graybug Vision, Inc. (GRAY)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Graybug Vision, Inc., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Graybug Vision, Inc. de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE